Moderna (NASDAQ:MRNA) Shares Down 5.2% After Analyst Downgrade

Shares of Moderna, Inc. (NASDAQ:MRNA) dropped 5.2% during trading on Monday after Leerink Partners lowered their price target on the stock from $18.00 to $15.00. Leerink Partners currently has an underperform rating on the stock. Moderna traded as low as $25.82 and last traded at $25.71. Approximately 4,869,262 shares traded hands during mid-day trading, a decline of 54% from the average daily volume of 10,628,141 shares. The stock had previously closed at $27.12.

Several other analysts have also recently issued reports on the stock. Cowen started coverage on shares of Moderna in a research note on Sunday, July 13th. They set a “hold” rating for the company. JPMorgan Chase & Co. set a $26.00 target price on Moderna in a report on Friday, August 1st. Barclays lowered their price target on Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a research report on Monday, August 4th. Bank of America dropped their price target on Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a research note on Tuesday, July 22nd. Finally, UBS Group reduced their price objective on Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $42.88.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. S Bank Fund Management Ltd acquired a new stake in Moderna in the first quarter valued at approximately $25,000. Rothschild Investment LLC grew its stake in shares of Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after acquiring an additional 446 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of Moderna during the second quarter valued at about $26,000. TD Private Client Wealth LLC lifted its stake in shares of Moderna by 348.8% in the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after acquiring an additional 743 shares in the last quarter. Finally, MUFG Securities EMEA plc acquired a new position in shares of Moderna in the second quarter worth about $28,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Price Performance

The business has a fifty day moving average of $29.16 and a 200 day moving average of $29.00. The stock has a market cap of $9.86 billion, a PE ratio of -3.37 and a beta of 1.83.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.Moderna’s revenue for the quarter was down 41.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.